Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Children and Adolescents With PNH
NCT03406507Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started Feb 2018; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03406507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406507.